Health Effects of Marijuana and Cannabinoids in Epilepsy

Note: This course is included in the Marij-thon™: Comprehensive Medical Marijuana Course.

Health Effects of Marijuana and Cannabinoids in Epilepsy describes how the endocannabinoid system may affect seizure threshold, and reviews the available research and clinical evidence for the use of marijuana or cannabinoids in the treatment of epilepsy. In addition, there is a discussion about an FDA-approved cannabis-based medicine for the treatment of Dravet syndrome and Lennox-Gastaut syndrome which are two rare and severe forms of epilepsy.

$50.00

Bulk pricing is available! Click here to learn more.

Overview

Health Effects of Marijuana and Cannabinoids in Epilepsy describes how the endocannabinoid system may affect seizure threshold, and reviews the available research and clinical evidence for the use of marijuana or cannabinoids in the treatment of epilepsy.  In addition, there is a discussion about an FDA-approved cannabis-based medicine for the treatment of Dravet syndrome and Lennox-Gastaut syndrome which are two rare and severe forms of epilepsy.

Subscribers can complete the curriculum and refer back to the content at any point during their 12-month subscription period.

Content provides Accreditation Council for Continuing Medical Education (ACCME),  Accreditation Council for Pharmacy Education (ACPE), American Association of Nurse Practitioners (AANP), American Nurses Credentialing Center (ANCC), and American Psychological Association (APA) credits.

I don’t plan on recommending marijuana…why would I take this course?

Whether or not you have any intention of recommending medical marijuana for patient care, you need to be well educated in this clinical area because your patients will be seeking your expert advice and guidance for this medication. Further, some of your patients may already be utilizing medical marijuana and you will need to be aware of its physiologic effects as well as its  potential drug interactions. As such, expertise in the endocannabinoid system and medical marijuana is paramount for most doctors, pharmacists, nurses, psychologists, and other allied health professionals to remain that respected guide for their patients’ overall healthcare.

Editorial Team

Editor-in-Chief:
Meredith Fisher-Corn, MD

Founding Editor-in-Chief:
Stephen B. Corn, MD

CME-Certified Activity

Target Audience

The educational design of this activity addresses the needs of physicians, nurses, nurse practitioners, pharmacists, and psychologists interested in the use of cannabinoids.

CME Certification

Content provides Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), American Association of Nurse Practitioners (AANP), American Nurses Credentialing Center (ANCC), and American Psychological Association (APA) credits.

This curriculum offers up to 0.5 hours of ACCME, ANCC, ACPE, AANP, and APA credit. Full accreditation information is available upon purchase.

Educational Objectives

After completing this activity, the participant should be better able to:

  • State the National Academies of Sciences, Engineering and Medicine’s conclusion on the use of cannabinoid-based products for the treatment of epilepsy that is published in The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research
  • Describe the available research examining the health effects of marijuana and cannabinoids in epilepsy
  • Explain how the endocannabinoid system is involved in epilepsy
  • Describe the ways in which CBD could possibly affect seizure activity in animal models of epilepsy
  • Describe the epidemiological evidence regarding marijuana use and seizure risk
  • Discuss an FDA-approved cannabis-based medicine for the treatment of two rare and severe forms of epilepsy
  • Describe Dravet syndrome

Global Contact Information

For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions for Obtaining Credit

In order to receive credit for this activity, the participant must complete the activity, pass the posttest with a score of 70% or greater, and fill out the activity evaluation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and The Answer Page do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Details

Credits: 0.5 CME/CE credits
Mobile-friendly: Yes